A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)

被引：0
作者：
Advani, Anjali S. [1 ]
Sobecks, Ronald [1 ]
Sekeres, Mikkael A. [1 ]
Copelan, Ed [1 ]
Bates, Jennifer [1 ]
Tripp, Barbara [1 ]
Salvado, August [2 ]
Kalaycio, Matt [1 ]
机构：
[1] Cleveland Clin, Leukemia Program, Cleveland, OH USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.906.906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
906
引用
收藏
页码：276A / 276A
页数：1
相关论文
共 50 条
  • [31] The Use of Clofarabine and Cytarabine Combination (CLARA) As Salvage Therapy for Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
    Leung, Anskar Y. H.
    Tse, Eric
    Liu, Herman S. Y.
    Sim, Joycelyn
    Kho, Bonnie C. S.
    Yip, Sze-Fai
    Lee, Harold K. K.
    Kwong, Yok Lam
    BLOOD, 2012, 120 (21)
  • [32] SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML)
    Advani, Anjali S.
    McDonough, Shannon
    Copelan, Edward
    Willman, Cheryl L.
    Mulford, Deborah A.
    List, Alan F.
    Sekeres, Mikkael A.
    Othus, Megan
    Erba, Harry P.
    Appelbaum, Frederick R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia
    Mirza, Abu-Sayeef
    Lancet, Jeffrey E.
    Sweet, Kendra
    Padron, Eric
    Pinilla-Ibarz, Javier
    Nardelli, Lisa
    Cubitt, Christopher
    List, Alan F.
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12) : 902 - 907
  • [34] A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
    Erba, Harry P.
    Oluwole, Olalekan O.
    Bixby, Dale
    Rampal, Raajit K.
    Fathi, Amir T.
    Paliwal, Prashni
    Jin, Jin
    Inoue, Ai
    Daver, Naval
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S311 - S312
  • [35] INDOXIMOD IN COMBINATION WITH IDARUBICIN AND CYTARABINE FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): PHASE 1 REPORT
    Emadi, A.
    Holtzman, N. G.
    Imran, M.
    El Chaer, F.
    Koka, M.
    Singh, Z.
    Shahlaee, A.
    Sausville, E. A.
    Law, J.
    Lee, S. T.
    Banerjee, A.
    Rapoport, A.
    Baer, M. R.
    Duong, V. H.
    Munn, D. H.
    Loken, M.
    Kennedy, E.
    Vahanian, N.
    Link, C.
    HAEMATOLOGICA, 2017, 102 : 375 - 375
  • [36] Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
    Sweet, Kendra
    Komrokji, Rami
    Padron, Eric
    Cubitt, Christopher L.
    Turner, Joel G.
    Zhou, Junmin
    List, Alan F.
    Sallman, David A.
    Dawson, Jana L.
    Sullivan, Daniel M.
    Chavez, Julio
    Shah, Bijal D.
    Lancet, Jeffrey E.
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 54 - 60
  • [37] Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation
    T Nanri
    N Matsuno
    T Kawakita
    H Mitsuya
    N Asou
    Leukemia, 2005, 19 : 1673 - 1675
  • [38] Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovesk, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 340A
  • [39] Treatment of elderly acute myeloid leukemia (AML) patients with the combination of mitoxantrone and cytarabine (MAC).
    Marinakis, T
    Galanopoulos, AG
    Zomas, A
    Michalis, E
    Gortzolidis, G
    Tsakiridou, A
    Xanthopoulos, V
    Theodoropoulos, G
    Goumakou, H
    Georgiakaki, M
    Grigoraki, V
    Anagnostopoulos, NI
    BLOOD, 2005, 106 (11) : 235B - 235B
  • [40] Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation
    Nanri, T
    Matsuno, N
    Kawakita, T
    Mitsuya, H
    Asou, N
    LEUKEMIA, 2005, 19 (09) : 1673 - 1675
12345